KUALA LUMPUR and LONDON, June 18, 2012 /PRNewswire/ --
New Osteoarthritis treatment for Malaysia
Pro Bono Bio™ is pleased to announce that its innovative product FLEXISEQ, a new nanotechnology based treatment for osteoarthritis, has received approval for sale in Malaysia. This follows the successful launch of FLEXISEQ in Europe earlier this year.
Pro Bono Bio is also pleased to announce that they have signed an agreement to distribute FLEXISEQ in Malaysia and the product will be available via local distribution company, Farmasia Sdn. Bhd. from early July 2012. Its first introduction to the local market is at the 42nd Annual Scientific Meeting of the Malaysian Orthopaedic Association in Kuantan, Malaysia held between the 14th and 17th of June 2012.
Michael Earl, COO of Pro Bono Bio, said "Pro Bono Bio is an ambitious new international pharmaceutical company which expects to make a real difference for patients, doctors and payors alike by developing truly innovative products to address areas of real need. It is a pleasure to launch our product FLEXISEQ here in Malaysia following our success in Europe. We look forward to introducing further innovative products this year and are also considering where to site our regional headquarters and manufacturing facilities to support our products in South East Asia."
Zohrah Razak Al Aidruss of Farmasia said "It is wonderful to have reached an agreement to introduce such an innovative product into Malaysia. The unique mode of action and lack of the side effects associated with various existing drug products, makes this a very welcome addition to the solutions available for physicians managing Osteoarthritis (OA). OA effects millions of patients in Malaysia, and both global and local trials have proved the effectiveness of FLEXISEQ at relieving joint pain associated with OA."
About Pro Bono Bio™
Pro Bono Bio is a new international healthcare company based on the experience in pharmaceutical product development, commercialisation and finance of Celtic Pharma Holdings in the UK, international capital, along with investment and support from RUSNANO in Russia. Pro Bono Bio has ambitious growth targets that will allow it to support a unique humanitarian mission.
Pro Bono Bio launched its first medical device, FLEXISEQ, a new nanotechnology based pain treatment for osteoarthritis, in Europe in the first half of 2012. The Company also plans to launch two further new products for the treatment of inflammatory skin disorders in the second half of 2012. These new products are based on Pro Bono Bio's innovative Sequessome Technology™.
Pro Bono Bio is also developing new products to treat haemophilia as well as novel antibiotics for the treatment of serious infections such as C. difficile, MRSA, Pneumonia and Tuberculosis.
FLEXISEQ is the safe way to reduce joint pain associated with osteoarthritis. FLEXISEQ benefits from a Class 2A Medical Device certification in Europe. It is a topically applied gel which uses the unique Sequessome Technology to pass through the skin and apply a biolubricant layer inside the effected joint and along the cartilage. This improves the mobility in the joint and reduces the pain.
For further information please contact:
Zohrah Ab Razak Al-Aidruss
To order in Malaysia please contact:
Farmasia Sdn. Bhd.
For London based press please contact:
Citigate Dewe Rogerson
David Dible / Nina Enegren
SOURCE Pro Bono Bio